Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-DHAP + high-dose methotrexate with intrathecal rituximab followed by autologous stem cell transplantation in recurrent aggressive B-cell lymphoma with CNS involvement
2006-002141-37Phase 2Active
- Sponsor
- HOVON
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in non-Hodgkin lymphoma (NHL) and malignant B-cell neoplasm, sponsored by HOVON. Primary endpoint: Response rate after R-DHAP + high-dose methotrexate with intrathecal rituximab. Started Jul 2006; status: active.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)malignant B-cell neoplasm
Beyond the preview
Go deeper on 2006-002141-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002141-37.